A PHASE I/II STUDY OF GENASENSE (G3139) IN COMBINATION WITH CISPLATIN AND FLUORO

GENASENSE (G3139) 与顺铂和氟联用的 I/II 期研究

• 批准号: 7378407
• 负责人: SCOTT H WADLER
• 金额: $ 0.97万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378407
• 关键词: PHASE; II; STUDY; GENASENSE; G3139

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives: The escalation portion of the study will determine the maximum tolerated dose (MTD) of G3139/ Cisplatin, and will help determine the toxicities of this combination. Primary endpoints of the phase II portion of the study will be response rate, time to progression, and median survival. Secondary objectives will be the collection of additional toxicity data for this combination. In patients who consent to biopsies the investigators will aim to determine the expression of a number of molecular markers and targets of G3139.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。主要目标：研究的升级部分将确定G3139/顺铂的最大耐受剂量（MTD），并将有助于确定该组合的毒性。该研究的II期部分的主要终点将是响应率，进展时间和中位生存期。 次要目标将是收集此组合的其他毒性数据。在同意活检的患者中，研究人员将旨在确定G3139的许多分子标记和靶标的表达。